William Blair reiterates Viking Therapeutic stock rating on clinical progress By Investing.com

Completed enrollment of ~1,100 patients in Phase 3 VANQUISH-2 (weekly injections over 78 weeks); Viking Therapeutics (VKTX) has a $3.88B market cap, is trading at $33.59 and is up 29.84% over the past six months. William Blair reiterated Outperform and highlighted VK2735 moving into Phase III roughly three years after Phase I; VANQUISH-1/-2 readouts are expected around mid-2027 and a Phase I maintenance readout is expected in Q3. Analysts reiterated bullish views with price targets ranging $35–$125 (Morgan Stanley $99, Jefferies $101, Truist $75, Raymond James $118), and the firm emphasized M&A optionality given oral and subcutaneous formulations plus a dual amylin/calcitonin receptor program.

Analysis

Viking's program architecture (same active molecule across induction and maintenance plus dual oral/subcutaneous optionality) creates a two-way value engine: clinical proof points drive label and payer positioning, while formulation optionality materially expands addressable prescribers and channels. That optionality is a second-order commercial de-risk — oral availability for maintenance compresses switch friction and could shorten time-to-reimbursed persistence, but it also raises COGS and supply-chain complexity (parallel oral and biologic manufacturing and distinct QC pathways) that will pressure gross margins early in commercialization.

From an M&A lens, Viking is a classic bolt-on target for large incumbents that want to plug formulation gaps without internal discovery risk; acquirers that lack an oral maintenance play gain immediate commercial optionality. However, acquirers will heavily discount upfront offers for execution risk (commercial roll-out, formulary access) and potential label/CMC delays — expect deal math to treat the asset like a de-risked clinical program but not a fully derisked launch franchise.

Key risks: a regulatory or tolerability signal in maintenance dosing would compress the valuation multiple far faster than a modest Phase 3 miss, and payer pushback on chronic maintenance pricing could limit peak revenues by 30-50% vs consensus if persistence or coverage fails. Catalysts to monitor are the near-term maintenance dataset (utility for dosing cadence and tolerability), any manufacturing/CMC updates, and how larger competitors adjust combo/maintenance strategies, which will materially affect optionality valuation over the next 12–18 months.

Key Decisions for Investors

• Initiate a tactical long position in VKTX (size 1–1.5% NAV) to capture optionality from maintenance and formulation optionality; pair with a hedged long-dated call structure: buy VKTX Jan 2028 40C and sell VKTX Jan 2026 40C to fund ~60–70% of cost. R/R: asymmetric upside if late-stage readouts and maintenance data are favorable; downside defined to equity loss minus option premium; stop-loss at -30% underlying move.
• Event-driven options play: buy VKTX Jul 2026 45C (smaller notional, ~0.25% NAV) ahead of the near-term maintenance dataset to exploit favorable IV skew on positive binary surprise. Target 3x return on positive readout; cut to loss at 50% premium decay or negative headline.
• Pair trade to isolate program-specific upside: long VKTX equity (1% NAV) vs short small-cap obesity index exposure (0.4x notional) to hedge sector beta — reduces vulnerability to broad GLP-1 volatility while keeping directional exposure to VKTX-specific catalysts.
• Risk-off hedge: buy put protection on large-cap obesity leader (e.g., LLY Jan 2027 550P, 0.25% NAV) if concerned about payor-led price compression across the class, as a severe pricing reset would propagate to acquirer appetite and compress small-cap M&A multiples rapidly.